IN2012DN02018A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02018A IN2012DN02018A IN2018DEN2012A IN2012DN02018A IN 2012DN02018 A IN2012DN02018 A IN 2012DN02018A IN 2018DEN2012 A IN2018DEN2012 A IN 2018DEN2012A IN 2012DN02018 A IN2012DN02018 A IN 2012DN02018A
- Authority
- IN
- India
- Prior art keywords
- hedgehog
- taxane
- inhibits
- administering
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23681309P | 2009-08-25 | 2009-08-25 | |
PCT/US2010/046684 WO2011025838A1 (en) | 2009-08-25 | 2010-08-25 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02018A true IN2012DN02018A (ru) | 2015-07-31 |
Family
ID=43628371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2018DEN2012 IN2012DN02018A (ru) | 2009-08-25 | 2010-08-25 |
Country Status (27)
Country | Link |
---|---|
US (2) | US20130045240A1 (ru) |
EP (2) | EP2470173B1 (ru) |
JP (1) | JP2013503174A (ru) |
KR (1) | KR20120053052A (ru) |
CN (1) | CN102573832B (ru) |
AU (1) | AU2010286670B2 (ru) |
BR (1) | BR112012004149A2 (ru) |
CA (1) | CA2772301A1 (ru) |
CR (1) | CR20120115A (ru) |
DK (1) | DK2470173T3 (ru) |
ES (1) | ES2577024T3 (ru) |
HK (1) | HK1172550A1 (ru) |
HR (1) | HRP20160551T8 (ru) |
HU (1) | HUE029094T2 (ru) |
IL (1) | IL218316A (ru) |
IN (1) | IN2012DN02018A (ru) |
MX (1) | MX340670B (ru) |
MY (1) | MY162514A (ru) |
NI (1) | NI201200030A (ru) |
NZ (1) | NZ598588A (ru) |
PL (1) | PL2470173T3 (ru) |
PT (1) | PT2470173E (ru) |
RU (1) | RU2561055C2 (ru) |
SG (2) | SG10201609290PA (ru) |
UA (1) | UA110196C2 (ru) |
WO (1) | WO2011025838A1 (ru) |
ZA (1) | ZA201201531B (ru) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CN104189905A (zh) * | 2005-08-31 | 2014-12-10 | 阿布拉科斯生物科学有限公司 | 包含水难溶性药剂和抗微生物剂的组合物 |
CN101605535A (zh) | 2006-12-14 | 2009-12-16 | 阿布拉科斯生物科学有限公司 | 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌 |
EP2481402B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
PT2155188E (pt) * | 2007-06-01 | 2013-12-19 | Abraxis Bioscience Llc | Métodos e composições para o tratamento de cancro recorrente |
EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
RU2559570C2 (ru) | 2009-04-15 | 2015-08-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции без приона на основе наночастиц и способы их получения |
ES2675212T3 (es) * | 2010-03-26 | 2018-07-09 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
JP6242213B2 (ja) | 2010-03-29 | 2017-12-06 | アブラクシス バイオサイエンス, エルエルシー | 薬物送達および治療用薬剤の有効性を向上させる方法 |
PL2552415T3 (pl) | 2010-03-29 | 2017-03-31 | Abraxis Bioscience, Llc | Sposoby leczenia nowotworu |
AU2011245441B2 (en) | 2010-04-29 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
BR112012030699A2 (pt) * | 2010-06-02 | 2016-09-13 | Abraxis Bioscience Llc | métodos para tratar câncer de bexiga |
MY162903A (en) * | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス, エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
US8779149B2 (en) * | 2010-08-23 | 2014-07-15 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
ME03532B (me) | 2011-12-14 | 2020-04-20 | Abraxis Bioscience Llc | Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje parтikula |
EP2806948B1 (en) | 2012-01-27 | 2020-01-15 | New York University | Method for enhancing remyelination using gli1 inhibitors |
CN103570625A (zh) * | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
CA2888360A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP2968254B1 (en) * | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
US9962373B2 (en) | 2013-03-14 | 2018-05-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
WO2014144747A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
WO2014179678A1 (en) * | 2013-05-03 | 2014-11-06 | Angiostrass Llc | Methods of treating cancer and angioproliferative disorders |
EP3004057B1 (en) | 2013-06-05 | 2018-07-25 | C&C Research Laboratories | Heterocyclic derivatives and their use as stat 3 inhibitors |
EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
BR112016004450A2 (pt) * | 2013-09-17 | 2017-10-17 | Genentech Inc | métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor |
GB201416513D0 (en) | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
CA2977521C (en) | 2015-02-27 | 2024-03-19 | Curtana Pharmaceuticals, Inc. | 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
DK3313401T3 (da) | 2015-06-29 | 2021-11-15 | Abraxis Bioscience Llc | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer |
CN106421786A (zh) * | 2015-08-06 | 2017-02-22 | 复旦大学 | Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途 |
JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
AU2019239953A1 (en) | 2018-03-20 | 2020-10-15 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
EP3976036A4 (en) * | 2019-05-29 | 2023-04-26 | Nelum Corporation | METHODS AND USES FOR THE TREATMENT OF CANCER |
KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
CN112755042A (zh) * | 2019-11-06 | 2021-05-07 | 绍兴维帆生物技术有限公司 | 一种抗肿瘤药物的联合使用治疗白血病的方法 |
KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
CA2294981C (en) * | 1997-06-27 | 2012-04-03 | Vivorx Pharmaceuticals, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
WO2000025725A2 (en) | 1998-11-02 | 2000-05-11 | Biogen, Inc. | Functional antagonists of hedgehog activity |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
EP1119368A2 (en) | 1999-03-03 | 2001-08-01 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
CA2375700A1 (en) | 1999-06-01 | 2000-12-07 | Biogen, Inc. | Polymer conjugates of hedgehog proteins and uses |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
US20050192262A1 (en) * | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
NZ530580A (en) | 2001-07-27 | 2007-02-23 | Curis Inc | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
DE60322869D1 (de) | 2002-04-22 | 2008-09-25 | Univ Johns Hopkins | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
JP2008514726A (ja) * | 2004-09-30 | 2008-05-08 | ザ ユニヴァーシティー オヴ シカゴ | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 |
CA2587489C (en) * | 2004-11-03 | 2013-12-31 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
KR20140016402A (ko) * | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
KR101457834B1 (ko) | 2005-08-31 | 2014-11-05 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법 |
EP1954284A4 (en) * | 2005-11-04 | 2010-01-06 | Merck & Co Inc | ANTICANCER TREATMENT OF SAHA AND PEMETREXED |
AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
US20080019961A1 (en) | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
DE102006038747A1 (de) | 2006-08-17 | 2008-03-20 | Khs Ag | Dichtanordnung für eine Drehlagervorrichtung |
JP4897518B2 (ja) | 2007-03-02 | 2012-03-14 | 株式会社ニチベイ | ブラインドの操作装置 |
SG179418A1 (en) * | 2007-03-14 | 2012-04-27 | Exelixis Patent Co Llc | Inhibitors of the hedgehog pathway |
KR101473504B1 (ko) * | 2007-03-15 | 2014-12-16 | 노파르티스 아게 | 유기 화합물 및 그의 용도 |
WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
EA200901610A1 (ru) * | 2007-06-07 | 2010-06-30 | Айрм Ллк | Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок |
US20090123932A1 (en) * | 2007-11-09 | 2009-05-14 | Anne-Marie Mes-Masson | Quantitative test to detect disease progression markers of epithelial ovarian cancer patients |
PE20091180A1 (es) | 2007-12-27 | 2009-08-26 | Infinity Pharmaceuticals Inc | Tratamientos terapeuticos contra el cancer |
JP5715420B2 (ja) * | 2007-12-28 | 2015-05-07 | ジェネンテック, インコーポレイテッド | 抗ヘッジホッグ抗体 |
-
2010
- 2010-08-25 HU HUE10812593A patent/HUE029094T2/hu unknown
- 2010-08-25 WO PCT/US2010/046684 patent/WO2011025838A1/en active Application Filing
- 2010-08-25 JP JP2012526948A patent/JP2013503174A/ja active Pending
- 2010-08-25 CA CA2772301A patent/CA2772301A1/en not_active Abandoned
- 2010-08-25 SG SG10201609290PA patent/SG10201609290PA/en unknown
- 2010-08-25 DK DK10812593.1T patent/DK2470173T3/en active
- 2010-08-25 EP EP10812593.1A patent/EP2470173B1/en active Active
- 2010-08-25 KR KR1020127007526A patent/KR20120053052A/ko not_active Application Discontinuation
- 2010-08-25 ES ES10812593.1T patent/ES2577024T3/es active Active
- 2010-08-25 PL PL10812593.1T patent/PL2470173T3/pl unknown
- 2010-08-25 UA UAA201203446A patent/UA110196C2/ru unknown
- 2010-08-25 CN CN201080045983.0A patent/CN102573832B/zh active Active
- 2010-08-25 AU AU2010286670A patent/AU2010286670B2/en active Active
- 2010-08-25 MY MYPI2012000838A patent/MY162514A/en unknown
- 2010-08-25 SG SG2012013157A patent/SG178873A1/en unknown
- 2010-08-25 BR BR112012004149A patent/BR112012004149A2/pt not_active Application Discontinuation
- 2010-08-25 IN IN2018DEN2012 patent/IN2012DN02018A/en unknown
- 2010-08-25 EP EP16167017.9A patent/EP3103452A1/en not_active Withdrawn
- 2010-08-25 NZ NZ598588A patent/NZ598588A/en not_active IP Right Cessation
- 2010-08-25 US US13/392,501 patent/US20130045240A1/en not_active Abandoned
- 2010-08-25 MX MX2012002460A patent/MX340670B/es active IP Right Grant
- 2010-08-25 PT PT108125931T patent/PT2470173E/pt unknown
- 2010-08-25 RU RU2012111235/15A patent/RU2561055C2/ru active
-
2012
- 2012-02-24 NI NI201200030A patent/NI201200030A/es unknown
- 2012-02-26 IL IL218316A patent/IL218316A/en active IP Right Grant
- 2012-02-29 ZA ZA2012/01531A patent/ZA201201531B/en unknown
- 2012-03-12 CR CR20120115A patent/CR20120115A/es unknown
- 2012-12-24 HK HK12113319.3A patent/HK1172550A1/zh unknown
-
2013
- 2013-02-28 US US13/781,487 patent/US20140072630A1/en not_active Abandoned
-
2016
- 2016-05-23 HR HRP20160551TT patent/HRP20160551T8/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02018A (ru) | ||
MY162903A (en) | Methods of treatment of pancreatic cancer | |
NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX346861B (es) | Metodos de tratamiento de carcinoma hepato celular. | |
MX2017007321A (es) | Terapias de combinacion. | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
MX346147B (es) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
GB201114051D0 (en) | Compounds and their uses | |
UA103614C2 (ru) | Лекарственное средство, содержащее комбинацию ингибитора киназы и анти-глипикан 3-антитела, для лечения рака печени | |
TN2013000227A1 (en) | Use of sigma ligands in bone cancer pain | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
MX2010009697A (es) | Tratamientos anticancerigenos mejorados. | |
MX2014010749A (es) | Composicion ginecologica para tratar la vestibulitis vulvar. | |
UA110795C2 (uk) | Спосіб лікування раку підшлункової залози | |
TNSN08062A1 (en) | Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin | |
TN2010000463A1 (en) | Compositions and methods for preparing and using same | |
TH135740A (th) | การบำบัดแบบรวมด้วยองค์ประกอบอนุภาคนาโนของแทกเซน และตัวยับยั้งเฮดจ์ฮอค | |
UA101610C2 (ru) | Наночастица, которая содержит рапамицин и альбумин, в качестве противоракового агента |